<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="182">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114499</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2021LSK-328</org_study_id>
    <nct_id>NCT05114499</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable.&#xD;
      Cholinesterase inhibitors, especially donepezil, are the first choice for mild and moderate&#xD;
      AD. Sodium oligomannate (GV-971) is a marine-derived oligosaccharide. It is proposed that it&#xD;
      can reconstitute the gut microbiota, and inhibit neuroinflammation in the brain as observed&#xD;
      in animal models. It reduces Aβ deposition in the brain of Aβ-transgenic mice. The reduction&#xD;
      in both Aβ deposition and neuroinflammation may synergistically contribute to the improvement&#xD;
      of cognitive impairment and delay the progress of the disease. The State Food and Drug&#xD;
      Administration of China (SFDA) approved it for the treatment of mild to moderate AD in 2019.&#xD;
      Due to the different mechanism of cholinesterase inhibitor and GV-971, theoretically, they&#xD;
      may synergistically improve cognitive function and delay disease progression. They are also&#xD;
      used in patients with AD, but there is a lack of data on their effectiveness and safety.&#xD;
      Therefore, the purpose of this observational study is to compare the efficacy and safety of&#xD;
      donepezil and GV-971 monotherapy and combination therapy in patients with mild and moderate&#xD;
      AD, which is of great significance for guiding the treatment of mild and moderate AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive function</measure>
    <time_frame>baseline, week 12, week 24, week 36</time_frame>
    <description>the change of Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog) score from baseline at week 36</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Donepezil monotherapy group</arm_group_label>
    <description>Donepezil 5mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GV-971 monotherapy group</arm_group_label>
    <description>GV-971 450mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Donepezil combined with GV-971 group</arm_group_label>
    <description>Donepezil 5mg qd+GV-971 450mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Donepezil 5mg qd</description>
    <arm_group_label>Donepezil combined with GV-971 group</arm_group_label>
    <arm_group_label>Donepezil monotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GV-971</intervention_name>
    <description>GV-971 450mg bid</description>
    <arm_group_label>Donepezil combined with GV-971 group</arm_group_label>
    <arm_group_label>GV-971 monotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients will be enrolled from our memory clinic and in-patients and should meet the&#xD;
        the National Institute of Neurological and Communicative Disorders and Stroke and the&#xD;
        Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (1984) criteria for&#xD;
        probable AD.The diagnosis of AD is mainly based on detail clinical history from caregivers,&#xD;
        neuropsychological testing, and brain MRI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age of 50-85 years old , either sex;&#xD;
&#xD;
          -  met the diagnostic criteria for suspected AD;&#xD;
&#xD;
          -  mild to moderate AD patients, that is, patients with 11 points ≤Mini-Mental State&#xD;
             Examination(MMSE) total score ≤26 points&#xD;
&#xD;
          -  total Hachinski ischemic scale (HIS) score ≤4 points;&#xD;
&#xD;
          -  memory loss for at least 12 months, with a tendency of progressive deterioration;&#xD;
&#xD;
          -  brain magnetic resonance imaging（MRI） scan suggesting a significant possibility of AD&#xD;
             ;&#xD;
&#xD;
          -  no obvious physical signs during nervous system examination;&#xD;
&#xD;
          -  stable and reliable caregivers,&#xD;
&#xD;
          -  elementary school or higher education level&#xD;
&#xD;
          -  signed an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous nervous system diseases (including stroke, optic neuromyelitis, Parkinson's&#xD;
             disease, epilepsy, etc.);&#xD;
&#xD;
          -  mental illness according to the Diagnostic and Statistical Manual of Mental Disorders,&#xD;
             4th Edition（DSM-IV), Text Revision criteria, including schizophrenia and other mental&#xD;
             illness, bipolar disorder, and severe depression or paralysis;&#xD;
&#xD;
          -  unstable or severe heart, lung, liver, kidney, or hematopoietic diseases;&#xD;
&#xD;
          -  uncorrectable visual and auditory disorders that affected completing&#xD;
             neuropsychological tests and scale assessments;&#xD;
&#xD;
          -  simultaneous use of cholinesterase inhibitors or memantine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Wang, doctor</last_name>
    <phone>+86 29 85324033</phone>
    <email>drwangjin@163.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

